Copyright © Inderes 2011 - present. All rights reserved.

Ascelia Pharma

2.955

 

SEK

 

+1.37 %

ACE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Less than 1K followers
Compare
+1.37%
+1.2%
-12.83%
+32.51%
-24.26%
-32.31%
-84.74%
-81.75%
-82.83%

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Read more
Market cap
287.21M SEK
Turnover
197.98K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Coverage
Disclaimer
Claus Thestrup
Claus Thestrup

CEO, Sweden

Latest research

Latest analysis report

Released: 21.10.2024

Financial calendar
7.2
2025

Annual report '24

7.5
2025

General meeting '25

16.5
2025

Interim report Q1'25

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Ascelia Pharma - What happened during Q3?
Webcast by
Claus Thestrup

Ascelia Pharma - What happened during Q3?

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 11 November at 2.00 PM. During the third quarter, Ascelia Pharma successfully completed its capital increase, allowing the company to focus on preparations for submitting the NDA for Orviglance and engaging with potential partners. In the last quarter of the year (Q4), Ascelia will receive the complete data package from the Orviglance SPARKLE Phase 3 study. Additionally, they will participate in the annual Radiological Society of North America conference in Chicago from December 1-5, 2024, where they will present abstracts from the SPARKLE study in an oral presentation.

Ascelia Pharma
Forum discussions
Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk: Ascelia Pharma er et svensk biotechselskab med fokus på lægemidler til cancer behandlinger. Selskabet udvikler og kommercialiserer lægemidler, der er målrettet mod medicinske behov som endnu ...
10/17/2022, 7:59 AM
by Olivier A. de Goeij
0
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.